相关实验视频

Updated: Apr 7, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

在性综合征中与利图西马布相关的不良事件:系统性审查和元分析

Zixian Yu¹, Meijin Huang², Yunlong Qin^1,3

¹Department of Nephrology, Xijing Hospital, Air Force Military Medical University, Xi'an, China.

|January 21, 2025

概括

利图西马布 (RTX) 显示了性综合征 (NS) 治疗的潜在安全性,在回顾性研究中不良事件 (AE) 较少. 需要进一步的高质量试验来确认NS患者的RTX安全性.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

脏综合征 (NS) 是一种脏疾病,其特点是尿液中大量的蛋白质流失.
单克隆抗体瑞图西马布 (RTX) 越来越多地用于NS,但其安全性需要彻底分析.
在NS治疗中RTX的定量安全数据有限.

研究的目的:

量化分析Rituximab (RTX) 在患有性综合征 (NS) 的患者的安全性.
为了比较与RTX相关的不良事件 (AE) 与NS的非RTX治疗.
在NS中确定与RTX治疗相关的特定安全问题和风险因素.

主要方法:

在PubMed,Embase和Cochrane注册的系统文献搜索到2023年12月31日.
包括随机对照试验 (RCT) 和回顾性研究,报告NS的RTX不良事件.
使用几率比率 (OR) 和风险差异 (RD) 与95%置信区间 (CI) 的AE的元分析.

主要成果:

分析了10项RCT和5项涉及1231名患者的回顾性研究.
在回顾性研究中,RTX显著降低了AEs总量 (OR=0.32),但在RCT中没有.
聚合输液反应率在RCT中为32%,在回顾性研究中为8%. 在成年NS患者和1000毫克RTX.观察到的血液事件的风险较低.
在RTX和非RTX组之间,严重的副作用,感染或其他重大不良事件没有显著差异.

结论:

与非RTX治疗NS相比,RTX显示出有希望的安全性,在回顾性分析中发现的整体副作用较少.
在使用RTX时,监测药物相互作用至关重要.
需要进行高质量的临床试验,以最终证实RTX在NS患者中的安全性.

关键词:

不良事件不良事件不良事件进行元分析分析.脏病综合征 - 脏病综合征里图西马布 (Rituximab) 是一种药物.系统性审查系统性审查

更多相关视频

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...